Keywords
How to Cite
Abstract
Since 2019, the Federal project “Cancer control” is being implemented in Russia. The main goal of the Federal project is to reduce mortality from malignant neoplasms by 2024.
The aim of the study is to assess impact of using novel antineoplastic drugs on the key performance indicators of the Federal Project.
Materials and methods. We used previously described methodology to assess impact of expanding use of osimertinib (in first line locally advanced or metastatic EGFRm+ NSCLC) and durvalumab (in maintenance therapy of unresectable locally advanced NSCLC after CRT and advanced SCLC in first line) on mortality from malignant neoplasms and one-year mortality rates. Data from foreign clinical trials and real-world evidence studies were used to model overall survival of patients treated with the considered treatment options.
Results.
Durvalumab and osimertinib could be additionally indicated for 4 053 and 1 596 patients annually in Russia. If all of them are treated with the considered drugs, mortality rate from neoplasms could be reduced by 1 682 cases over three years (508 cases in 2023, 644 cases in 2024, and 531 cases in 2025). Increased use of osimertinib and durvalumab in late-stage lung cancer could reduce one-year mortality from malignant neoplasms by 0.11 percentage points and among lung cancer patients by 1.18 percentage points.
Conclusions.
Using novel antineoplastic drugs for lung cancer treatment in different clinical situations leads to quantitate reduction in cancer mortality in Russia.
References
ЛИТЕРАТУРА
Casal-Mouriño A, Ruano-Ravina A, Lorenzo-González M, et al Epidemiology of stage III lung cancer: frequency, diagnostic characteristics, and survival. Transl Lung Cancer Res. 2021;10(1):506518. doi:10.21037/tlcr.2020.03.40.
Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol. 2006;7(9):71927. doi:10.1016/S1470-2045(06)70804-X.
Duma N, Santana-Davila R, Molina JR. Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin Proc. 2019;94(8):16231640. doi:10.1016/j.mayocp.2019.01.013.
Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):5165. doi:10.1016/S1470-2045(20)30539-8.
Han B, Tjulandin S, Hagiwara K, Normanno N, Wulandari L, Konstantin Konstantinovich L, et al. Determining the Prevalence of EGFR Mutations in Asian and Russian Patients (PTS) with Advanced Non-Small-Cell Lung Cancer (ANSCLC) of Adenocarcinoma (ADC) and Non-Adc Histology: Ignite Study. Annals of Oncology [Internet]. 2015;26:i29. doi:10.1093/annonc/mdv050.01.
Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol. 2008;26(15):24506. doi:10.1200/JCO.2007.14.4824.
Ramalingam SS, Vansteenkiste J, Planchard D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382(1):4150. doi:10.1056/NEJMoa1913662.
Spigel DR, Faivre-Finn C, Gray JE, et al. Five-year survival outcomes from the PACIFIC trial: Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. J Clin Oncol. 2022;40(12):13011311. doi:10.1200/JCO.21.01308.
Авксентьев Н., Сисигина Н., Фролов М. и др. Оценка вклада применения современных противоопухолевых лекарственных препаратов в достижение целей федерального проекта по борьбе с онкозаболеваниями. Вопросы онкологии. 2021;67(6):768–76 [Avxentyev N, Sisigina N, Frolov M, Makarov A. Analysis of novel antineoplastic drugs treatment impact on the federal project «cancer control» goals achievement. Problems in oncology. 2021;67(6):768–76 (In Russ.)]. doi:10.37469/0507-3758-2021-67-6-768-776.
Лактионов К.К., Артамонова Е.В., Борисова Т.Н., и др. Злокачественное новообразование бронхов и легкого. Клинические рекомендации. 2022;24(3):269–304 [Laktionov KK, Artamonova EV, Borisova TN, et al. Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. 2022;24(3):269–304. (In Russ.)]. Available from: https://cr.minzdrav.gov.ru/recomend/30_4. doi:0.26442/18151434.2022.3.201848.
Инструкция по медицинскому применению лекарственного препарата для медицинского применения Имфинзи (дурвалумаб). Государственный реестр лекарственных средств Министерства здравоохранения РФ. [Электронный ресурс]. [Instructions for medical use of the pharmaceutical product Imfinzi (durvalumab). State registry of medicinal products of the Ministry of Health of the Russian Federation. [Internet]. (In Russ.)]. Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=1ac0a5d2-3904-4113-a7de-ca73f42df281.
Инструкция по медицинскому применению лекарственного препарата для медицинского применения Тагриссо (осимертиниб). Государственный реестр лекарственных средств Министерства здравоохранения РФ. [Электронный ресурс]. [Instructions for medical use of the pharmaceutical product Tagrisso (osimertinib). State registry of medicinal products of the Ministry of Health of the Russian Federation. [Internet]. (In Russ.)]. Available from: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=9a5ab6b9-3bbb-4fc7-a7af-41d1d99e2786.
Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2021 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена. Филиал ФГБУ «ФМИЦ им. П.А. Герцена» Минздрава России. 2022:250 [Kaprin A.D., Starinsky V.V., Petrova G.V. Malignant neoplasms in Russia in 2021 (morbidity and mortality). P. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation. 2022:250 (In Russ.)].
Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2021 году. М.: МНИОИ им. П.А. Герцена. Филиал ФГБУ «НМИРЦ» Минздрава России. 2022:236 [Kaprin A.D., Starinsky V.V., Petrova G.V. State of Cancer Care in Russia in 2021. Moscow: P. Hertsen Moscow Oncology Research Institute - branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation. 2022:236 (In Russ.)].
Мариниченко Н.В., Лактионов К.К., Назаренко А.В. и др. Методы комбинированной химиолучевой терапии и их эффективность в лечении больных немелкоклеточным раком легкого неоперабельной III стадии: обзор литературы. Медицинский Совет. 2019;(10):92–8 [Marinichenko NV, Laktionov KK, Nazarenko AV, et al. Combined chemoradiotherapy regimens and their effectiveness in the treatment of patients with non-small-cell unresectable stage III lung cancer: review of literature. Medical Council. 2019;(10):92–8 (In Russ.)] doi:10.21518/2079-701x-2019-10-92-98.
Постановление Правительства РФ от 31 марта 2021 г. N 512 "О внесении изменений в государственную программу Российской Федерации "Развитие здравоохранения". [Электронный ресурс]. [Decree of the Government of the Russian Federation of March 31, 2021 N 512 «On Amendments to the State Program of the Russian Federation "Development of Healthcare"». [Internet] (In Russ.)]. Available from: http://publication.pravo.gov.ru/Document/View/0001202104070027?index=6&rangeSize=1.
Росстат — ЕМИСС. [Электронный ресурс]. [Rosstat – EMISS [Internet] (In Russ.)]. Available from: https://www.fedstat.ru/.
Ряженов В. В., Орлов С. В., Ивахненко О. И. Влияние препарата дурвалумаб на достижение целевого показателя «снижение смертности населения от новообразований» при распространенном мелкоклеточном раке легкого. Современная онкология. 2022;24(1):30–40 [Ryazhenov VV, Orlov SV, Ivakhnenko OI. Assessment of the impact of the use of durvalumab for the treatment of advanced small cell lung cancer on the achievement of the target «reduction in mortality from neoplasms». Journal of Modern Oncology. 2022;24(1):30–40. (In Russ.).]. doi:10.26442/18151434.2022.1.201498.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
© АННМО «Вопросы онкологии», Copyright (c) 2023